The Contact Dermatitis drugs in development market research report provides comprehensive information on the therapeutics under development for Contact Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Contact Dermatitis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued products.

GlobalData tracks 11 drugs in development for Contact Dermatitis by ten companies/universities/institutes. The top development phase for Contact Dermatitis is preclinical with five drugs in that stage. The Contact Dermatitis pipeline has ten drugs in development by companies and one by universities/ institutes. Some of the companies in the Contact Dermatitis pipeline products market are: Edesa Biotech, Allakos and Tianjin Institute of Pharmaceutical Research.

The key targets in the Contact Dermatitis pipeline products market include Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1), Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B), and Prostaglandin D2 Receptor (Prostanoid DP Receptor or PTGDR).

The key mechanisms of action in the Contact Dermatitis pipeline product include Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist with one drug in Phase III. The Contact Dermatitis pipeline products include seven routes of administration with the top ROA being Topical and five key molecule types in the Contact Dermatitis pipeline products market including Small Molecule, and Monoclonal Antibody.

Contact Dermatitis overview

Contact dermatitis is a type of skin inflammation that occurs when substances touching the skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps and dry, cracked, red patches, which may resemble a burn, and pain or tenderness. There are two types of contact dermatitis: irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to an allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching.

For a complete picture of Contact Dermatitis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.